WEBVTT
Kind: captions
Language: en

00:00:02.240 --> 00:00:07.430 

we<00:00:03.240> make<00:00:03.449> cell<00:00:03.810> therapy<00:00:04.350> work<00:00:04.620> for<00:00:04.890> you<00:00:05.930> AB<00:00:06.930> set

00:00:07.430 --> 00:00:07.440 
we make cell therapy work for you AB set

00:00:07.440 --> 00:00:09.530 
we make cell therapy work for you AB set
located<00:00:08.160> in<00:00:08.280> gross<00:00:08.580> Hardin<00:00:09.030> and<00:00:09.210> in<00:00:09.360> auto

00:00:09.530 --> 00:00:09.540 
located in gross Hardin and in auto

00:00:09.540 --> 00:00:11.680 
located in gross Hardin and in auto
Braun<00:00:09.870> in<00:00:10.019> Munich<00:00:10.469> is<00:00:10.800> an<00:00:11.040> innovative

00:00:11.680 --> 00:00:11.690 
Braun in Munich is an innovative

00:00:11.690 --> 00:00:13.490 
Braun in Munich is an innovative
biopharmaceutical<00:00:12.690> company<00:00:13.080> and<00:00:13.290> is

00:00:13.490 --> 00:00:13.500 
biopharmaceutical company and is

00:00:13.500 --> 00:00:15.410 
biopharmaceutical company and is
regarded<00:00:13.650> throughout<00:00:14.130> the<00:00:14.460> world<00:00:14.700> as<00:00:15.150> one<00:00:15.389> of

00:00:15.410 --> 00:00:15.420 
regarded throughout the world as one of

00:00:15.420 --> 00:00:17.060 
regarded throughout the world as one of
the<00:00:15.570> pioneers<00:00:16.139> in<00:00:16.289> the<00:00:16.379> development<00:00:16.949> and

00:00:17.060 --> 00:00:17.070 
the pioneers in the development and

00:00:17.070 --> 00:00:19.279 
the pioneers in the development and
production<00:00:17.250> of<00:00:17.760> innovative<00:00:18.390> cell<00:00:18.720> therapy

00:00:19.279 --> 00:00:19.289 
production of innovative cell therapy

00:00:19.289 --> 00:00:23.060 
production of innovative cell therapy
products<00:00:20.570> the<00:00:21.570> Santana's<00:00:21.900> self<00:00:22.410> on<00:00:22.560> exit<00:00:22.949> the

00:00:23.060 --> 00:00:23.070 
products the Santana's self on exit the

00:00:23.070 --> 00:00:25.519 
products the Santana's self on exit the
company<00:00:23.490> objective<00:00:24.029> of<00:00:24.180> ad<00:00:24.449> set<00:00:24.779> is<00:00:25.230> to

00:00:25.519 --> 00:00:25.529 
company objective of ad set is to

00:00:25.529 --> 00:00:27.980 
company objective of ad set is to
develop<00:00:25.830> and<00:00:26.220> produce<00:00:26.340> new<00:00:27.029> pharmaceutical

00:00:27.980 --> 00:00:27.990 
develop and produce new pharmaceutical

00:00:27.990 --> 00:00:29.839 
develop and produce new pharmaceutical
products<00:00:28.560> for<00:00:28.859> the<00:00:28.949> treatment<00:00:29.250> of<00:00:29.550> malignant

00:00:29.839 --> 00:00:29.849 
products for the treatment of malignant

00:00:29.849 --> 00:00:32.150 
products for the treatment of malignant
diseases<00:00:30.510> for<00:00:31.170> which<00:00:31.230> there<00:00:31.650> are<00:00:31.769> currently

00:00:32.150 --> 00:00:32.160 
diseases for which there are currently

00:00:32.160 --> 00:00:35.209 
diseases for which there are currently
no<00:00:32.279> satisfactory<00:00:33.270> therapy<00:00:34.079> options<00:00:34.230> curtain

00:00:35.209 --> 00:00:35.219 
no satisfactory therapy options curtain

00:00:35.219 --> 00:00:38.569 
no satisfactory therapy options curtain
begins<00:00:35.550> and<00:00:35.989> in<00:00:36.989> particular<00:00:37.399> apset<00:00:38.399> is

00:00:38.569 --> 00:00:38.579 
begins and in particular apset is

00:00:38.579 --> 00:00:40.400 
begins and in particular apset is
concerned<00:00:39.030> with<00:00:39.239> closing<00:00:39.540> the<00:00:39.809> gap<00:00:40.050> between

00:00:40.400 --> 00:00:40.410 
concerned with closing the gap between

00:00:40.410 --> 00:00:44.479 
concerned with closing the gap between
research<00:00:40.890> and<00:00:41.160> clinical<00:00:41.730> application<00:00:43.489> to

00:00:44.479 --> 00:00:44.489 
research and clinical application to

00:00:44.489 --> 00:00:46.729 
research and clinical application to
achieve<00:00:44.760> this<00:00:44.910> objective<00:00:45.140> apset<00:00:46.140> makes<00:00:46.410> use

00:00:46.729 --> 00:00:46.739 
achieve this objective apset makes use

00:00:46.739 --> 00:00:48.860 
achieve this objective apset makes use
of<00:00:46.800> adult<00:00:47.399> stem<00:00:47.670> cells<00:00:48.030> or<00:00:48.300> other<00:00:48.539> non

00:00:48.860 --> 00:00:48.870 
of adult stem cells or other non

00:00:48.870 --> 00:00:52.130 
of adult stem cells or other non
embryonic<00:00:49.620> body<00:00:49.890> cells<00:00:50.329> adult<00:00:51.329> mesenchymal

00:00:52.130 --> 00:00:52.140 
embryonic body cells adult mesenchymal

00:00:52.140 --> 00:00:54.830 
embryonic body cells adult mesenchymal
stem<00:00:52.620> or<00:00:52.949> stromal<00:00:53.489> cells<00:00:53.760> are<00:00:54.270> found<00:00:54.420> in<00:00:54.629> many

00:00:54.830 --> 00:00:54.840 
stem or stromal cells are found in many

00:00:54.840 --> 00:00:57.020 
stem or stromal cells are found in many
organs<00:00:55.350> of<00:00:55.500> the<00:00:55.620> human<00:00:55.980> body<00:00:56.129> especially<00:00:56.579> in

00:00:57.020 --> 00:00:57.030 
organs of the human body especially in

00:00:57.030 --> 00:01:00.979 
organs of the human body especially in
bone<00:00:57.300> marrow<00:00:58.850> however<00:00:59.850> peripheral<00:01:00.600> adult

00:01:00.979 --> 00:01:00.989 
bone marrow however peripheral adult

00:01:00.989 --> 00:01:03.080 
bone marrow however peripheral adult
stromal<00:01:01.590> cells<00:01:01.890> also<00:01:02.219> circulate<00:01:02.879> in<00:01:03.059> the

00:01:03.080 --> 00:01:03.090 
stromal cells also circulate in the

00:01:03.090 --> 00:01:05.660 
stromal cells also circulate in the
bloodstream<00:01:03.470> they<00:01:04.470> are<00:01:04.619> easy<00:01:04.830> to<00:01:04.949> obtain<00:01:05.189> and

00:01:05.660 --> 00:01:05.670 
bloodstream they are easy to obtain and

00:01:05.670 --> 00:01:08.530 
bloodstream they are easy to obtain and
their<00:01:06.000> use<00:01:06.240> is<00:01:06.420> ethically<00:01:06.869> unobjectionable

00:01:08.530 --> 00:01:08.540 
their use is ethically unobjectionable

00:01:08.540 --> 00:01:10.940 
their use is ethically unobjectionable
these<00:01:09.540> cells<00:01:09.810> have<00:01:09.930> a<00:01:10.049> wide<00:01:10.380> range<00:01:10.710> of

00:01:10.940 --> 00:01:10.950 
these cells have a wide range of

00:01:10.950 --> 00:01:14.990 
these cells have a wide range of
biological<00:01:11.700> properties<00:01:13.189> as<00:01:14.189> a<00:01:14.490> topical

00:01:14.990 --> 00:01:15.000 
biological properties as a topical

00:01:15.000 --> 00:01:17.270 
biological properties as a topical
therapy<00:01:15.060> concept<00:01:15.990> of<00:01:16.140> AB<00:01:16.380> set<00:01:16.650> is<00:01:16.799> based<00:01:17.070> on

00:01:17.270 --> 00:01:17.280 
therapy concept of AB set is based on

00:01:17.280 --> 00:01:19.370 
therapy concept of AB set is based on
the<00:01:17.430> cell<00:01:17.729> being<00:01:18.060> the<00:01:18.210> actual<00:01:18.570> drug<00:01:18.869> that<00:01:19.200> is

00:01:19.370 --> 00:01:19.380 
the cell being the actual drug that is

00:01:19.380 --> 00:01:21.140 
the cell being the actual drug that is
not<00:01:19.530> something<00:01:19.710> new<00:01:20.189> but<00:01:20.460> has<00:01:20.670> been<00:01:20.880> known

00:01:21.140 --> 00:01:21.150 
not something new but has been known

00:01:21.150 --> 00:01:23.060 
not something new but has been known
from<00:01:21.479> stem<00:01:21.869> cell<00:01:22.200> and<00:01:22.439> bone<00:01:22.740> marrow

00:01:23.060 --> 00:01:23.070 
from stem cell and bone marrow

00:01:23.070 --> 00:01:25.550 
from stem cell and bone marrow
transplantation<00:01:23.880> for<00:01:24.299> many<00:01:24.479> decades<00:01:24.750> however

00:01:25.550 --> 00:01:25.560 
transplantation for many decades however

00:01:25.560 --> 00:01:27.800 
transplantation for many decades however
these<00:01:25.890> cells<00:01:26.250> which<00:01:26.549> are<00:01:26.729> already<00:01:27.150> in<00:01:27.330> use<00:01:27.570> are

00:01:27.800 --> 00:01:27.810 
these cells which are already in use are

00:01:27.810 --> 00:01:29.960 
these cells which are already in use are
being<00:01:28.049> further<00:01:28.439> developed<00:01:29.040> by<00:01:29.159> us<00:01:29.340> as<00:01:29.579> drugs

00:01:29.960 --> 00:01:29.970 
being further developed by us as drugs

00:01:29.970 --> 00:01:32.090 
being further developed by us as drugs
in<00:01:30.270> line<00:01:30.570> with<00:01:30.840> pharmaceutical<00:01:31.619> standards

00:01:32.090 --> 00:01:32.100 
in line with pharmaceutical standards

00:01:32.100 --> 00:01:34.219 
in line with pharmaceutical standards
something<00:01:32.759> that<00:01:32.939> can<00:01:33.210> then<00:01:33.360> benefit<00:01:33.960> patients

00:01:34.219 --> 00:01:34.229 
something that can then benefit patients

00:01:34.229 --> 00:01:38.649 
something that can then benefit patients
across<00:01:34.710> a<00:01:34.799> wide<00:01:35.159> variety<00:01:35.430> of<00:01:35.880> indications

00:01:38.649 --> 00:01:38.659 
across a wide variety of indications

00:01:38.659 --> 00:01:41.090 
across a wide variety of indications
apset<00:01:39.659> adopts<00:01:40.110> two<00:01:40.320> approaches<00:01:40.710> and

00:01:41.090 --> 00:01:41.100 
apset adopts two approaches and

00:01:41.100 --> 00:01:43.370 
apset adopts two approaches and
development<00:01:41.670> of<00:01:41.759> new<00:01:41.970> therapy<00:01:42.509> methods<00:01:42.720> using

00:01:43.370 --> 00:01:43.380 
development of new therapy methods using

00:01:43.380 --> 00:01:46.490 
development of new therapy methods using
adult<00:01:43.860> mesenchymal<00:01:44.310> stromal<00:01:45.000> cells<00:01:45.509> somatic

00:01:46.490 --> 00:01:46.500 
adult mesenchymal stromal cells somatic

00:01:46.500 --> 00:01:48.620 
adult mesenchymal stromal cells somatic
cell<00:01:46.740> therapy<00:01:47.220> with<00:01:47.460> stem<00:01:47.820> cells<00:01:47.850> found<00:01:48.420> in

00:01:48.620 --> 00:01:48.630 
cell therapy with stem cells found in

00:01:48.630 --> 00:01:50.510 
cell therapy with stem cells found in
the<00:01:48.780> body<00:01:48.930> as<00:01:49.350> well<00:01:49.680> as<00:01:49.799> the<00:01:49.890> development<00:01:50.430> of

00:01:50.510 --> 00:01:50.520 
the body as well as the development of

00:01:50.520 --> 00:01:52.609 
the body as well as the development of
therapies<00:01:51.060> with<00:01:51.270> modified<00:01:51.780> adult<00:01:52.320> cells

00:01:52.609 --> 00:01:52.619 
therapies with modified adult cells

00:01:52.619 --> 00:01:54.980 
therapies with modified adult cells
these<00:01:53.520> cells<00:01:53.579> offer<00:01:54.180> potentially<00:01:54.840> a<00:01:54.869> very

00:01:54.980 --> 00:01:54.990 
these cells offer potentially a very

00:01:54.990 --> 00:01:58.300 
these cells offer potentially a very
broad<00:01:55.500> range<00:01:55.920> of<00:01:56.130> medical<00:01:56.579> applications

00:01:58.300 --> 00:01:58.310 
broad range of medical applications

00:01:58.310 --> 00:02:01.190 
broad range of medical applications
the<00:01:59.310> mechanism<00:01:59.850> of<00:01:59.910> action<00:02:00.120> of<00:02:00.450> cell<00:02:00.750> therapy

00:02:01.190 --> 00:02:01.200 
the mechanism of action of cell therapy

00:02:01.200 --> 00:02:03.530 
the mechanism of action of cell therapy
is<00:02:01.350> basically<00:02:01.860> simple<00:02:02.160> the<00:02:02.790> pharmaceutically

00:02:03.530 --> 00:02:03.540 
is basically simple the pharmaceutically

00:02:03.540 --> 00:02:05.600 
is basically simple the pharmaceutically
produced<00:02:03.960> cells<00:02:04.290> are<00:02:04.530> first<00:02:04.770> introduced<00:02:05.400> into

00:02:05.600 --> 00:02:05.610 
produced cells are first introduced into

00:02:05.610 --> 00:02:07.610 
produced cells are first introduced into
the<00:02:05.790> bloodstream<00:02:06.030> for<00:02:06.750> example<00:02:07.170> by<00:02:07.320> short

00:02:07.610 --> 00:02:07.620 
the bloodstream for example by short

00:02:07.620 --> 00:02:09.740 
the bloodstream for example by short
infusion<00:02:08.280> there<00:02:08.760> they<00:02:09.000> circulate<00:02:09.570> in<00:02:09.720> the

00:02:09.740 --> 00:02:09.750 
infusion there they circulate in the

00:02:09.750 --> 00:02:12.770 
infusion there they circulate in the
blood<00:02:09.990> naturally<00:02:10.940> specific<00:02:11.940> signals<00:02:12.420> from<00:02:12.630> a

00:02:12.770 --> 00:02:12.780 
blood naturally specific signals from a

00:02:12.780 --> 00:02:15.380 
blood naturally specific signals from a
body<00:02:12.990> organ<00:02:13.470> or<00:02:13.650> tissue<00:02:13.680> then<00:02:14.520> ensure<00:02:14.940> that

00:02:15.380 --> 00:02:15.390 
body organ or tissue then ensure that

00:02:15.390 --> 00:02:17.360 
body organ or tissue then ensure that
the<00:02:15.540> cells<00:02:15.810> are<00:02:15.960> attracted<00:02:16.530> to<00:02:16.680> injured<00:02:17.190> or

00:02:17.360 --> 00:02:17.370 
the cells are attracted to injured or

00:02:17.370 --> 00:02:19.730 
the cells are attracted to injured or
inflamed<00:02:17.760> tissue<00:02:18.120> as<00:02:18.540> well<00:02:18.840> as<00:02:18.990> tumors<00:02:19.500> or

00:02:19.730 --> 00:02:19.740 
inflamed tissue as well as tumors or

00:02:19.740 --> 00:02:22.520 
inflamed tissue as well as tumors or
their<00:02:19.920> metastasis<00:02:21.230> because<00:02:22.230> of<00:02:22.380> their

00:02:22.520 --> 00:02:22.530 
their metastasis because of their

00:02:22.530 --> 00:02:24.620 
their metastasis because of their
biological<00:02:23.340> properties<00:02:23.640> the<00:02:24.360> cells

00:02:24.620 --> 00:02:24.630 
biological properties the cells

00:02:24.630 --> 00:02:27.200 
biological properties the cells
therefore<00:02:24.960> migrate<00:02:25.620> and<00:02:25.920> targeted<00:02:26.520> manner<00:02:26.760> to

00:02:27.200 --> 00:02:27.210 
therefore migrate and targeted manner to

00:02:27.210 --> 00:02:28.850 
therefore migrate and targeted manner to
where<00:02:27.420> they<00:02:27.600> are<00:02:27.630> needed<00:02:27.990> and<00:02:28.410> where<00:02:28.680> they

00:02:28.850 --> 00:02:28.860 
where they are needed and where they

00:02:28.860 --> 00:02:31.270 
where they are needed and where they
then<00:02:29.070> can<00:02:29.280> exert<00:02:29.700> their<00:02:30.030> therapeutic<00:02:30.570> effect

00:02:31.270 --> 00:02:31.280 
then can exert their therapeutic effect

00:02:31.280 --> 00:02:33.860 
then can exert their therapeutic effect
this<00:02:32.280> means<00:02:32.610> that<00:02:32.760> the<00:02:32.940> South<00:02:33.210> starts<00:02:33.690> to

00:02:33.860 --> 00:02:33.870 
this means that the South starts to

00:02:33.870 --> 00:02:36.260 
this means that the South starts to
release<00:02:34.230> the<00:02:34.500> specific<00:02:35.070> drug<00:02:35.400> added<00:02:35.850> to<00:02:35.970> it<00:02:36.090> by

00:02:36.260 --> 00:02:36.270 
release the specific drug added to it by

00:02:36.270 --> 00:02:39.020 
release the specific drug added to it by
apset<00:02:36.810> technology<00:02:37.440> exactly<00:02:38.400> where<00:02:38.610> the<00:02:38.760> tumor

00:02:39.020 --> 00:02:39.030 
apset technology exactly where the tumor

00:02:39.030 --> 00:02:42.350 
apset technology exactly where the tumor
is<00:02:39.210> growing<00:02:39.650> in<00:02:40.650> this<00:02:40.950> way<00:02:41.160> tumor<00:02:41.850> growth<00:02:42.150> is

00:02:42.350 --> 00:02:42.360 
is growing in this way tumor growth is

00:02:42.360 --> 00:02:44.330 
is growing in this way tumor growth is
hindered<00:02:42.870> in<00:02:43.020> a<00:02:43.200> sustained<00:02:43.740> manner<00:02:44.040> and

00:02:44.330 --> 00:02:44.340 
hindered in a sustained manner and

00:02:44.340 --> 00:02:46.640 
hindered in a sustained manner and
potentially<00:02:45.210> the<00:02:45.600> tumor<00:02:46.020> is<00:02:46.050> destroyed

00:02:46.640 --> 00:02:46.650 
potentially the tumor is destroyed

00:02:46.650 --> 00:02:50.720 
potentially the tumor is destroyed
completely<00:02:48.110> now<00:02:49.110> 10<00:02:49.290> BC<00:02:49.440> our<00:02:49.800> experience<00:02:50.490> so

00:02:50.720 --> 00:02:50.730 
completely now 10 BC our experience so

00:02:50.730 --> 00:02:52.880 
completely now 10 BC our experience so
far<00:02:50.760> indicates<00:02:51.570> that<00:02:51.690> cell<00:02:52.110> therapy<00:02:52.590> in<00:02:52.680> this

00:02:52.880 --> 00:02:52.890 
far indicates that cell therapy in this

00:02:52.890 --> 00:02:55.160 
far indicates that cell therapy in this
form<00:02:53.160> has<00:02:53.370> far<00:02:53.670> fewer<00:02:53.700> side<00:02:54.300> effects<00:02:54.690> or<00:02:54.870> even

00:02:55.160 --> 00:02:55.170 
form has far fewer side effects or even

00:02:55.170 --> 00:02:57.950 
form has far fewer side effects or even
none<00:02:55.380> at<00:02:55.530> all<00:02:55.680> will<00:02:56.040> be<00:02:56.160> acquired<00:02:56.780> since<00:02:57.780> its

00:02:57.950 --> 00:02:57.960 
none at all will be acquired since its

00:02:57.960 --> 00:03:00.920 
none at all will be acquired since its
founding<00:02:58.380> in<00:02:58.670> 2007<00:02:59.670> apset<00:03:00.420> has<00:03:00.570> entered

00:03:00.920 --> 00:03:00.930 
founding in 2007 apset has entered

00:03:00.930 --> 00:03:02.960 
founding in 2007 apset has entered
completely<00:03:01.410> uncharted<00:03:01.920> territory<00:03:02.700> in<00:03:02.820> the

00:03:02.960 --> 00:03:02.970 
completely uncharted territory in the

00:03:02.970 --> 00:03:05.000 
completely uncharted territory in the
development<00:03:03.510> of<00:03:03.600> innovative<00:03:03.870> cell<00:03:04.470> therapy

00:03:05.000 --> 00:03:05.010 
development of innovative cell therapy

00:03:05.010 --> 00:03:07.760 
development of innovative cell therapy
products<00:03:05.459> every<00:03:06.330> individual<00:03:06.990> working<00:03:07.440> step

00:03:07.760 --> 00:03:07.770 
products every individual working step

00:03:07.770 --> 00:03:10.130 
products every individual working step
all<00:03:08.130> methods<00:03:08.490> used<00:03:09.000> have<00:03:09.390> been<00:03:09.420> developed<00:03:10.020> and

00:03:10.130 --> 00:03:10.140 
all methods used have been developed and

00:03:10.140 --> 00:03:12.020 
all methods used have been developed and
established<00:03:10.709> from<00:03:10.920> scratch<00:03:11.310> at<00:03:11.580> the<00:03:11.670> company

00:03:12.020 --> 00:03:12.030 
established from scratch at the company

00:03:12.030 --> 00:03:14.240 
established from scratch at the company
headquarters<00:03:12.180> in<00:03:12.810> grows<00:03:13.110> harder<00:03:13.500> at<00:03:14.010> the<00:03:14.100> same

00:03:14.240 --> 00:03:14.250 
headquarters in grows harder at the same

00:03:14.250 --> 00:03:16.400 
headquarters in grows harder at the same
time<00:03:14.310> apset<00:03:15.120> also<00:03:15.660> works<00:03:15.930> in<00:03:16.140> close

00:03:16.400 --> 00:03:16.410 
time apset also works in close

00:03:16.410 --> 00:03:18.260 
time apset also works in close
cooperation<00:03:16.709> with<00:03:17.310> scientists<00:03:17.970> and

00:03:18.260 --> 00:03:18.270 
cooperation with scientists and

00:03:18.270 --> 00:03:22.210 
cooperation with scientists and
researchers<00:03:18.390> from<00:03:19.020> academic<00:03:19.650> institutions

00:03:22.210 --> 00:03:22.220 
researchers from academic institutions

00:03:22.220 --> 00:03:24.650 
researchers from academic institutions
thanks<00:03:23.220> to<00:03:23.340> a<00:03:23.370> highly<00:03:23.790> committed<00:03:24.090> team<00:03:24.450> of

00:03:24.650 --> 00:03:24.660 
thanks to a highly committed team of

00:03:24.660 --> 00:03:26.900 
thanks to a highly committed team of
qualified<00:03:24.840> employees<00:03:25.830> apset<00:03:26.640> has<00:03:26.760> already

00:03:26.900 --> 00:03:26.910 
qualified employees apset has already

00:03:26.910 --> 00:03:29.229 
qualified employees apset has already
achieved<00:03:27.270> much<00:03:27.840> since<00:03:28.230> its<00:03:28.380> foundation<00:03:28.739> in

00:03:29.229 --> 00:03:29.239 
achieved much since its foundation in

00:03:29.239 --> 00:03:32.690 
achieved much since its foundation in
2007<00:03:30.260> apset<00:03:31.260> obtained<00:03:31.680> the<00:03:31.830> first<00:03:32.130> official

00:03:32.690 --> 00:03:32.700 
2007 apset obtained the first official

00:03:32.700 --> 00:03:34.850 
2007 apset obtained the first official
authorization<00:03:32.880> for<00:03:33.840> so-called<00:03:34.050> genetic

00:03:34.850 --> 00:03:34.860 
authorization for so-called genetic

00:03:34.860 --> 00:03:37.610 
authorization for so-called genetic
engineering<00:03:35.430> as<00:03:35.700> early<00:03:35.970> as<00:03:36.120> the<00:03:36.330> end<00:03:36.360> of<00:03:36.750> 2008

00:03:37.610 --> 00:03:37.620 
engineering as early as the end of 2008

00:03:37.620 --> 00:03:40.820 
engineering as early as the end of 2008
in<00:03:38.480> 2010<00:03:39.480> apset<00:03:40.140> was<00:03:40.320> granted<00:03:40.739> a

00:03:40.820 --> 00:03:40.830 
in 2010 apset was granted a

00:03:40.830 --> 00:03:43.130 
in 2010 apset was granted a
manufacturing<00:03:41.640> license<00:03:42.090> for<00:03:42.360> somatic<00:03:42.870> cell

00:03:43.130 --> 00:03:43.140 
manufacturing license for somatic cell

00:03:43.140 --> 00:03:45.110 
manufacturing license for somatic cell
therapy<00:03:43.680> products<00:03:44.100> from<00:03:44.550> the<00:03:44.700> district

00:03:45.110 --> 00:03:45.120 
therapy products from the district

00:03:45.120 --> 00:03:47.150 
therapy products from the district
government<00:03:45.390> of<00:03:45.660> upper<00:03:45.930> bavaria<00:03:46.110> and<00:03:46.590> the<00:03:46.920> paul

00:03:47.150 --> 00:03:47.160 
government of upper bavaria and the paul

00:03:47.160 --> 00:03:51.030 
government of upper bavaria and the paul
ali<00:03:47.459> institute

00:03:51.030 --> 00:03:51.040 

00:03:51.040 --> 00:03:54.640 

in<00:03:52.040> the<00:03:52.280> summer<00:03:52.519> of<00:03:52.610> 2011<00:03:53.540> apps<00:03:54.260> it<00:03:54.530> was

00:03:54.640 --> 00:03:54.650 
in the summer of 2011 apps it was

00:03:54.650 --> 00:03:56.589 
in the summer of 2011 apps it was
granted<00:03:54.950> an<00:03:55.280> extended<00:03:55.879> manufacturing

00:03:56.589 --> 00:03:56.599 
granted an extended manufacturing

00:03:56.599 --> 00:03:58.210 
granted an extended manufacturing
license<00:03:56.989> for<00:03:57.230> the<00:03:57.290> new<00:03:57.500> development<00:03:58.069> and

00:03:58.210 --> 00:03:58.220 
license for the new development and

00:03:58.220 --> 00:04:00.280 
license for the new development and
production<00:03:58.370> center<00:03:59.060> in<00:03:59.180> Auto<00:03:59.390> Braun<00:03:59.780> Munich

00:04:00.280 --> 00:04:00.290 
production center in Auto Braun Munich

00:04:00.290 --> 00:04:03.130 
production center in Auto Braun Munich
all<00:04:01.220> together<00:04:01.670> this<00:04:01.879> new<00:04:02.120> facility<00:04:02.330> covers

00:04:03.130 --> 00:04:03.140 
all together this new facility covers

00:04:03.140 --> 00:04:05.979 
all together this new facility covers
1,800<00:04:03.980> square<00:04:04.340> metres<00:04:04.760> including<00:04:05.480> an<00:04:05.569> area<00:04:05.930> of

00:04:05.979 --> 00:04:05.989 
1,800 square metres including an area of

00:04:05.989 --> 00:04:08.789 
1,800 square metres including an area of
almost<00:04:06.170> 500<00:04:06.950> square<00:04:07.160> meters<00:04:07.459> of<00:04:07.670> clean<00:04:08.060> rooms

00:04:08.789 --> 00:04:08.799 
almost 500 square meters of clean rooms

00:04:08.799 --> 00:04:11.680 
almost 500 square meters of clean rooms
together<00:04:09.799> with<00:04:10.190> the<00:04:10.310> GMP<00:04:10.670> facilities<00:04:11.480> in

00:04:11.680 --> 00:04:11.690 
together with the GMP facilities in

00:04:11.690 --> 00:04:13.809 
together with the GMP facilities in
gross<00:04:11.959> hardened<00:04:12.440> the<00:04:12.799> app<00:04:12.980> set<00:04:13.280> cleanroom

00:04:13.809 --> 00:04:13.819 
gross hardened the app set cleanroom

00:04:13.819 --> 00:04:16.120 
gross hardened the app set cleanroom
areas<00:04:14.269> comprise<00:04:14.810> a<00:04:14.930> total<00:04:15.349> of<00:04:15.470> six<00:04:15.650> hundred

00:04:16.120 --> 00:04:16.130 
areas comprise a total of six hundred

00:04:16.130 --> 00:04:18.490 
areas comprise a total of six hundred
square<00:04:16.400> meters<00:04:16.669> spread<00:04:17.449> over<00:04:17.600> five<00:04:17.930> separate

00:04:18.490 --> 00:04:18.500 
square meters spread over five separate

00:04:18.500 --> 00:04:22.510 
square meters spread over five separate
cleanroom<00:04:19.100> Swedes<00:04:20.620> the<00:04:21.620> units<00:04:22.039> are<00:04:22.100> equipped

00:04:22.510 --> 00:04:22.520 
cleanroom Swedes the units are equipped

00:04:22.520 --> 00:04:24.610 
cleanroom Swedes the units are equipped
with<00:04:22.639> storage<00:04:23.210> tanks<00:04:23.630> for<00:04:23.810> liquid<00:04:24.169> nitrogen

00:04:24.610 --> 00:04:24.620 
with storage tanks for liquid nitrogen

00:04:24.620 --> 00:04:26.920 
with storage tanks for liquid nitrogen
for<00:04:25.100> storing<00:04:25.460> cell<00:04:25.729> preparations<00:04:26.419> and<00:04:26.660> with<00:04:26.900> a

00:04:26.920 --> 00:04:26.930 
for storing cell preparations and with a

00:04:26.930 --> 00:04:28.870 
for storing cell preparations and with a
total<00:04:27.199> of<00:04:27.410> six<00:04:27.710> incubators<00:04:28.430> for<00:04:28.460> Sal

00:04:28.870 --> 00:04:28.880 
total of six incubators for Sal

00:04:28.880 --> 00:04:31.360 
total of six incubators for Sal
expansion<00:04:29.800> they<00:04:30.800> are<00:04:30.949> monitored

00:04:31.360 --> 00:04:31.370 
expansion they are monitored

00:04:31.370 --> 00:04:33.370 
expansion they are monitored
round-the-clock<00:04:31.820> by<00:04:32.240> the<00:04:32.300> in-house<00:04:32.780> quality

00:04:33.370 --> 00:04:33.380 
round-the-clock by the in-house quality

00:04:33.380 --> 00:04:37.090 
round-the-clock by the in-house quality
control<00:04:33.800> department<00:04:35.650> here<00:04:36.650> at<00:04:36.680> the<00:04:36.949> Auto

00:04:37.090 --> 00:04:37.100 
control department here at the Auto

00:04:37.100 --> 00:04:39.129 
control department here at the Auto
brune<00:04:37.520> facility<00:04:38.150> we<00:04:38.330> develop<00:04:38.840> and<00:04:38.990> produce

00:04:39.129 --> 00:04:39.139 
brune facility we develop and produce

00:04:39.139 --> 00:04:41.350 
brune facility we develop and produce
cell<00:04:39.650> therapy<00:04:40.130> products<00:04:40.520> for<00:04:40.789> our<00:04:41.030> own

00:04:41.350 --> 00:04:41.360 
cell therapy products for our own

00:04:41.360 --> 00:04:43.150 
cell therapy products for our own
projects<00:04:42.020> as<00:04:42.139> well<00:04:42.169> as<00:04:42.440> for<00:04:42.620> our<00:04:42.800> customers

00:04:43.150 --> 00:04:43.160 
projects as well as for our customers

00:04:43.160 --> 00:04:46.810 
projects as well as for our customers
and<00:04:43.520> cooperation<00:04:44.419> partners<00:04:45.280> so<00:04:46.280> thanks<00:04:46.760> to

00:04:46.810 --> 00:04:46.820 
and cooperation partners so thanks to

00:04:46.820 --> 00:04:49.390 
and cooperation partners so thanks to
the<00:04:47.000> additional<00:04:47.449> capacities<00:04:48.139> apset<00:04:48.979> is<00:04:49.190> in<00:04:49.310> a

00:04:49.390 --> 00:04:49.400 
the additional capacities apset is in a

00:04:49.400 --> 00:04:51.370 
the additional capacities apset is in a
position<00:04:49.550> to<00:04:49.850> undertake<00:04:50.600> projects<00:04:51.139> in<00:04:51.289> the

00:04:51.370 --> 00:04:51.380 
position to undertake projects in the

00:04:51.380 --> 00:04:53.350 
position to undertake projects in the
development<00:04:51.949> and<00:04:52.039> production<00:04:52.250> of<00:04:52.699> innovative

00:04:53.350 --> 00:04:53.360 
development and production of innovative

00:04:53.360 --> 00:04:55.839 
development and production of innovative
cell<00:04:53.630> therapy<00:04:54.139> product<00:04:54.530> as<00:04:54.710> a<00:04:54.770> qualified<00:04:55.639> and

00:04:55.839 --> 00:04:55.849 
cell therapy product as a qualified and

00:04:55.849 --> 00:04:58.270 
cell therapy product as a qualified and
efficient<00:04:56.419> partner<00:04:56.840> with<00:04:57.260> both<00:04:57.470> cooperation

00:04:58.270 --> 00:04:58.280 
efficient partner with both cooperation

00:04:58.280 --> 00:05:04.089 
efficient partner with both cooperation
partners<00:04:58.580> and<00:04:58.849> customers<00:05:02.590> apset<00:05:03.590> reached<00:05:03.889> the

00:05:04.089 --> 00:05:04.099 
partners and customers apset reached the

00:05:04.099 --> 00:05:06.190 
partners and customers apset reached the
first<00:05:04.340> milestone<00:05:04.729> in<00:05:05.330> its<00:05:05.450> objective<00:05:06.020> to

00:05:06.190 --> 00:05:06.200 
first milestone in its objective to

00:05:06.200 --> 00:05:08.140 
first milestone in its objective to
close<00:05:06.470> the<00:05:06.680> gap<00:05:06.710> between<00:05:07.220> research<00:05:07.669> and

00:05:08.140 --> 00:05:08.150 
close the gap between research and

00:05:08.150 --> 00:05:10.060 
close the gap between research and
clinical<00:05:08.389> application<00:05:09.289> in<00:05:09.470> the<00:05:09.650> spring<00:05:09.950> of

00:05:10.060 --> 00:05:10.070 
clinical application in the spring of

00:05:10.070 --> 00:05:13.029 
clinical application in the spring of
2011<00:05:10.910> when<00:05:11.539> it<00:05:11.660> started<00:05:12.050> the<00:05:12.169> first<00:05:12.440> clinical

00:05:13.029 --> 00:05:13.039 
2011 when it started the first clinical

00:05:13.039 --> 00:05:15.129 
2011 when it started the first clinical
trial<00:05:13.400> with<00:05:13.700> adult<00:05:14.090> mesenchymal<00:05:14.479> stromal

00:05:15.129 --> 00:05:15.139 
trial with adult mesenchymal stromal

00:05:15.139 --> 00:05:18.310 
trial with adult mesenchymal stromal
cells<00:05:15.620> MSC<00:05:16.490> app<00:05:16.700> set<00:05:17.120> is<00:05:17.389> extruded<00:05:17.870> Faust's

00:05:18.310 --> 00:05:18.320 
cells MSC app set is extruded Faust's

00:05:18.320 --> 00:05:19.960 
cells MSC app set is extruded Faust's
this<00:05:18.500> study<00:05:18.830> deals<00:05:19.190> with<00:05:19.490> peripheral

00:05:19.960 --> 00:05:19.970 
this study deals with peripheral

00:05:19.970 --> 00:05:23.080 
this study deals with peripheral
circulatory<00:05:20.930> disorders<00:05:21.229> and<00:05:21.860> using<00:05:22.760> cell

00:05:23.080 --> 00:05:23.090 
circulatory disorders and using cell

00:05:23.090 --> 00:05:26.409 
circulatory disorders and using cell
therapy<00:05:23.660> with<00:05:23.870> MSC<00:05:24.349> upset<00:05:25.099> we<00:05:25.639> are<00:05:25.669> trying<00:05:26.120> to

00:05:26.409 --> 00:05:26.419 
therapy with MSC upset we are trying to

00:05:26.419 --> 00:05:28.510 
therapy with MSC upset we are trying to
achieve<00:05:26.570> an<00:05:27.050> additional<00:05:27.590> possible<00:05:28.070> means<00:05:28.340> of

00:05:28.510 --> 00:05:28.520 
achieve an additional possible means of

00:05:28.520 --> 00:05:30.550 
achieve an additional possible means of
improving<00:05:28.880> circulation<00:05:29.450> in<00:05:30.110> the<00:05:30.139> legs<00:05:30.229> of

00:05:30.550 --> 00:05:30.560 
improving circulation in the legs of

00:05:30.560 --> 00:05:32.469 
improving circulation in the legs of
patients<00:05:31.130> with<00:05:31.280> peripheral<00:05:31.760> circulatory

00:05:32.469 --> 00:05:32.479 
patients with peripheral circulatory

00:05:32.479 --> 00:05:35.350 
patients with peripheral circulatory
disorders<00:05:32.979> so<00:05:33.979> that's<00:05:34.160> healed<00:05:34.400> so<00:05:35.120> what<00:05:35.300> about

00:05:35.350 --> 00:05:35.360 
disorders so that's healed so what about

00:05:35.360 --> 00:05:38.469 
disorders so that's healed so what about
a<00:05:35.479> nomad<00:05:36.229> these<00:05:37.010> are<00:05:37.280> telling<00:05:37.789> to<00:05:38.060> date<00:05:38.270> we

00:05:38.469 --> 00:05:38.479 
a nomad these are telling to date we

00:05:38.479 --> 00:05:39.940 
a nomad these are telling to date we
have<00:05:38.510> not<00:05:38.810> been<00:05:38.990> able<00:05:39.139> to<00:05:39.380> detect<00:05:39.680> any

00:05:39.940 --> 00:05:39.950 
have not been able to detect any

00:05:39.950 --> 00:05:41.890 
have not been able to detect any
negative<00:05:40.430> features<00:05:40.880> in<00:05:41.030> either<00:05:41.150> removal<00:05:41.780> or

00:05:41.890 --> 00:05:41.900 
negative features in either removal or

00:05:41.900 --> 00:05:44.710 
negative features in either removal or
returning<00:05:42.289> of<00:05:42.590> these<00:05:42.770> cells<00:05:43.099> and<00:05:43.539> what<00:05:44.539> is

00:05:44.710 --> 00:05:44.720 
returning of these cells and what is

00:05:44.720 --> 00:05:46.870 
returning of these cells and what is
especially<00:05:45.320> important<00:05:45.860> the<00:05:46.190> patients<00:05:46.729> have

00:05:46.870 --> 00:05:46.880 
especially important the patients have

00:05:46.880 --> 00:05:49.270 
especially important the patients have
reported<00:05:46.910> a<00:05:47.570> significant<00:05:48.380> increase<00:05:48.620> in<00:05:48.889> their

00:05:49.270 --> 00:05:49.280 
reported a significant increase in their

00:05:49.280 --> 00:05:51.700 
reported a significant increase in their
well-being<00:05:49.570> following<00:05:50.570> this<00:05:50.750> cell<00:05:51.110> returning

00:05:51.700 --> 00:05:51.710 
well-being following this cell returning

00:05:51.710 --> 00:05:53.379 
well-being following this cell returning
procedure<00:05:52.130> the<00:05:52.550> pain<00:05:52.820> that<00:05:53.060> they<00:05:53.210> have

00:05:53.379 --> 00:05:53.389 
procedure the pain that they have

00:05:53.389 --> 00:05:55.270 
procedure the pain that they have
reported<00:05:53.900> so<00:05:54.110> far<00:05:54.139> has<00:05:54.620> been<00:05:54.650> decreasing

00:05:55.270 --> 00:05:55.280 
reported so far has been decreasing

00:05:55.280 --> 00:06:00.180 
reported so far has been decreasing
significantly<00:05:55.900> with<00:05:56.900> your<00:05:57.139> fig<00:05:57.380> it<00:05:57.530> isn't

00:06:00.180 --> 00:06:00.190 

00:06:00.190 --> 00:06:03.310 

yet<00:06:01.190> loud<00:06:01.400> we<00:06:01.820> believe<00:06:02.150> that<00:06:02.180> cell<00:06:02.780> therapy

00:06:03.310 --> 00:06:03.320 
yet loud we believe that cell therapy

00:06:03.320 --> 00:06:05.140 
yet loud we believe that cell therapy
complements<00:06:03.950> other<00:06:04.130> therapies<00:06:04.730> and<00:06:04.940> gives

00:06:05.140 --> 00:06:05.150 
complements other therapies and gives

00:06:05.150 --> 00:06:06.880 
complements other therapies and gives
hope<00:06:05.390> to<00:06:05.420> and<00:06:05.840> provide<00:06:06.200> solutions<00:06:06.500> for

00:06:06.880 --> 00:06:06.890 
hope to and provide solutions for

00:06:06.890 --> 00:06:08.560 
hope to and provide solutions for
patients<00:06:07.580> who<00:06:07.700> have<00:06:07.880> previously<00:06:08.180> been

00:06:08.560 --> 00:06:08.570 
patients who have previously been

00:06:08.570 --> 00:06:12.130 
patients who have previously been
without<00:06:09.020> hope<00:06:10.330> nothing<00:06:11.330> bosver<00:06:11.540> here<00:06:11.900> Nelly

00:06:12.130 --> 00:06:12.140 
without hope nothing bosver here Nelly

00:06:12.140 --> 00:06:13.810 
without hope nothing bosver here Nelly
after<00:06:12.440> what<00:06:12.620> we've<00:06:12.800> developed<00:06:13.130> and<00:06:13.490> achieved

00:06:13.810 --> 00:06:13.820 
after what we've developed and achieved

00:06:13.820 --> 00:06:16.150 
after what we've developed and achieved
here<00:06:14.030> adapts<00:06:14.450> it<00:06:14.600> in<00:06:14.720> recent<00:06:15.110> years<00:06:15.140> we<00:06:15.920> see<00:06:16.130> a

00:06:16.150 --> 00:06:16.160 
here adapts it in recent years we see a

00:06:16.160 --> 00:06:17.980 
here adapts it in recent years we see a
unique<00:06:16.550> potential<00:06:17.090> for<00:06:17.270> cell<00:06:17.480> therapy

00:06:17.980 --> 00:06:17.990 
unique potential for cell therapy

00:06:17.990 --> 00:06:19.690 
unique potential for cell therapy
products<00:06:18.380> to<00:06:18.740> offer<00:06:18.950> the<00:06:19.040> possibility<00:06:19.190> of

00:06:19.690 --> 00:06:19.700 
products to offer the possibility of

00:06:19.700 --> 00:06:21.790 
products to offer the possibility of
treatment<00:06:20.180> for<00:06:20.300> diseases<00:06:20.660> in<00:06:20.960> the<00:06:21.050> future<00:06:21.470> for

00:06:21.790 --> 00:06:21.800 
treatment for diseases in the future for

00:06:21.800 --> 00:06:23.470 
treatment for diseases in the future for
which<00:06:21.920> there<00:06:22.190> are<00:06:22.280> currently<00:06:22.640> no<00:06:22.760> treatment

00:06:23.470 --> 00:06:23.480 
which there are currently no treatment

00:06:23.480 --> 00:06:24.970 
which there are currently no treatment
options<00:06:23.900> available<00:06:24.200> European<00:06:24.770> of<00:06:24.890> the

00:06:24.970 --> 00:06:24.980 
options available European of the

00:06:24.980 --> 00:06:29.140 
options available European of the
pregnant<00:06:26.320> apset<00:06:27.320> we<00:06:28.010> may<00:06:28.190> excel<00:06:28.580> therapy<00:06:29.120> a

00:06:29.140 --> 00:06:29.150 
pregnant apset we may excel therapy a

00:06:29.150 --> 00:06:31.870 
pregnant apset we may excel therapy a
work<00:06:29.420> for<00:06:29.690> you

